RxDoctor Payments Data

Eric Kim, MD

Ophthalmology · Naperville, ILNPI 1326576968

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.1% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Alcon at 29.0% of the total. Reporting peaked in 2024 at $517 and has fallen 66.1% since, to $175 in 2025.

$1,605in general payments, 2019–2025

Across 35 payments — averaging $45.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$465
  • Sun Pharmaceutical Industries Inc.$312
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$150
  • Sight Sciences, Inc.$144
  • Bausch & Lomb Americas Inc.$124
  • Glaukos Corporation$105
  • plus $304 from 9 others
$14,520in research payments, 2019–2025

Across 3 payments — averaging $4840.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Exactech, Inc.$15K

What the payments were for

  • Food & beverage$1,59199%
  • Entertainment$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,605 in reported general payments places this provider in the 55th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois →

Medicare billing

Part B allowed, 2024
$139,513
Medicare patients
480
Services billed
1,105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Latanoprost175$2,559
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat49$754
Prednisolone Acetate27$754
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha57$578
Timolol Maleate38$449
Brimonidine Tartrate58$423
Dorzolamide Hcl14$248
Doxycycline Hyclate12$141

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Naperville

See the full list for Illinois →

Where these figures come from

Is this you, or does something look wrong? →